Novavax‘s vaccine candidate will not likely be the first to market, but will stand in contrast to the mRNA vaccines by Moderna and Pfeizer. As I understand it, mRNA biotechnology allows for faster scaled production. However, it is brand-new technology which has never been used commercially in humans. The way mRNA vaccines work is scary and sounds very close to genetic engineering or editing. In contrast, Novavax uses a tried-and-true method to produce immunity. News media and social media are almost certain to hype up reports of side effects during the first round of vaccination. Vaccine hesitancy is growing, and in 2018 almost half of US citizens refused a flu vaccine. Waiting a few more months for Novavax‘s vaccine candidate would appeal to vaccine hesitant individuals who are not fully anti-vax.
Source: https://www.statista.com/topics/5166/vaccine-hesitancy-in-the-us/
Investment advice offered through Magnifina, LLC, a Registered Investment Adviser. SEC# 801-117932. This website and information are provided for guidance and information purposes only and are not intended to provide investment, tax, or legal advice. No historical or future performance claims are made. Please consult a qualified professional before making decisions about your financial situation or otherwise using any specific information contained herein.
Any linked materials are provided strictly as a courtesy. We make no representation as to the completeness or accuracy of information provided at these websites. When you access one of these websites, you are leaving our website and assume total responsibility and risk for your use of the websites you are viewing.
Any service described as “free” or “complimentary” means there is no monetary or financial cost to you. However, these offers may require you to be in contact with us, provide certain information, or participate in meetings or consultations. We reserve the right to deny, discontinue, or limit access to any offer at our sole discretion.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
25 Broadway, 10th Floor
New York, NY 10004
Phone: (800) 732-0818
